These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 8863572)
1. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. Takeuchi S; Arai K; Saitoh H; Yoshida K; Miura M J Urol; 1996 Nov; 156(5):1691-5. PubMed ID: 8863572 [TBL] [Abstract][Full Text] [Related]
2. [The clinical usefulness of urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer]. Takeuchi S; Saitoh H Nihon Rinsho; 1998 Aug; 56(8):2077-81. PubMed ID: 9750511 [TBL] [Abstract][Full Text] [Related]
3. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346 [TBL] [Abstract][Full Text] [Related]
4. Sequential changes of urinary pyridinoline and deoxypyridinoline as markers of metastatic bone tumor in patients with prostate cancer: a preliminary study. Samma S; Kagebayashi Y; Yasukawa M; Fukui Y; Ozono S; Hirao Y; Sato H; Okajima E Jpn J Clin Oncol; 1997 Feb; 27(1):26-30. PubMed ID: 9070337 [TBL] [Abstract][Full Text] [Related]
5. [Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate of bone resorption: usefulness of urinary pyridinoline and deoxypyridinoline in patients with prostate cancer with bone metastases]. Takeuchi S; Yoshida K Nihon Hinyokika Gakkai Zasshi; 1994 Oct; 85(10):1521-7. PubMed ID: 7990300 [TBL] [Abstract][Full Text] [Related]
6. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastasis. Sano M; Kushida K; Takahashi M; Ohishi T; Kawana K; Okada M; Inoue T Br J Cancer; 1994 Oct; 70(4):701-3. PubMed ID: 7917922 [TBL] [Abstract][Full Text] [Related]
7. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Ikeda I; Miura T; Kondo I Br J Urol; 1996 Jan; 77(1):102-6. PubMed ID: 8653278 [TBL] [Abstract][Full Text] [Related]
8. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis. Wymenga LF; Groenier K; Schuurman J; Boomsma JH; Elferink RO; Mensink HJ BJU Int; 2001 Aug; 88(3):231-5. PubMed ID: 11488735 [TBL] [Abstract][Full Text] [Related]
9. Bone-turnover metabolites as clinical markers of bone metastasis in patients with prostatic carcinoma. Takeuchi S; Saitoh H Int J Urol; 1997 Jul; 4(4):368-73. PubMed ID: 9256326 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer. Westerhuis LW; Delaere KP Eur J Clin Chem Clin Biochem; 1997 Feb; 35(2):89-94. PubMed ID: 9056749 [TBL] [Abstract][Full Text] [Related]
11. Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Chung JH; Park MS; Kim YS; Chang J; Kim JH; Kim SK; Kim SK Yonsei Med J; 2005 Jun; 46(3):388-93. PubMed ID: 15988811 [TBL] [Abstract][Full Text] [Related]
12. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer. Noguchi M; Noda S J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307 [TBL] [Abstract][Full Text] [Related]
13. Serum concentration of the pyridinoline crosslinked carboxyterminal telopeptide of type I collagen and urinary concentration of deoxypyridinoline as markers of bone metastases in human prostate carcinoma. Yoshida K; Hosoya Y; Arai K; Sumi S; Honda M Clin Chim Acta; 1996 Oct; 254(1):93-5. PubMed ID: 8894314 [No Abstract] [Full Text] [Related]
14. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975 [TBL] [Abstract][Full Text] [Related]
15. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer. Li C; Zang T; Wrobel K; Huang JT; Nabi G Anal Bioanal Chem; 2015 May; 407(12):3393-404. PubMed ID: 25724369 [TBL] [Abstract][Full Text] [Related]
16. Bone remodeling markers in the detection of bone metastases in prostate cancer. de la Piedra C; Castro-Errecaborde NA; Traba ML; Méndez-Dávila C; García-Moreno C; Rodriguez de Acuña L; Rodriguez-Molina J Clin Chim Acta; 2003 May; 331(1-2):45-53. PubMed ID: 12691863 [TBL] [Abstract][Full Text] [Related]
17. The diagnostic value of urinary Crosslaps and serum alkaline phosphatase in patients with prostate cancer. Nguyen-Pamart M; Caty A; Feutrie ML; Fournier C; Gosselin P; Mazeman E Br J Urol; 1997 Sep; 80(3):452-5. PubMed ID: 9313666 [TBL] [Abstract][Full Text] [Related]
18. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma. Papatheofanis FJ J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144 [TBL] [Abstract][Full Text] [Related]
19. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459 [TBL] [Abstract][Full Text] [Related]
20. Serum pyridinoline crosslinks as markers of tumour-induced bone resorption. Nemoto R; Nakamura I; Nishijima Y; Shiobara K; Shimizu M; Takehara T; Ohta T; Kiyoki M Br J Urol; 1997 Aug; 80(2):274-80. PubMed ID: 9284202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]